179 related articles for article (PubMed ID: 11443220)
1. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
Kitazono M; Robey R; Zhan Z; Sarlis NJ; Skarulis MC; Aikou T; Bates S; Fojo T
J Clin Endocrinol Metab; 2001 Jul; 86(7):3430-5. PubMed ID: 11443220
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
Furuya F; Shimura H; Suzuki H; Taki K; Ohta K; Haraguchi K; Onaya T; Endo T; Kobayashi T
Endocrinology; 2004 Jun; 145(6):2865-75. PubMed ID: 14976143
[TBL] [Abstract][Full Text] [Related]
3. Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.
Kitazono M; Chuman Y; Aikou T; Fojo T
J Clin Endocrinol Metab; 2001 Feb; 86(2):834-40. PubMed ID: 11158054
[TBL] [Abstract][Full Text] [Related]
4. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy.
Imanishi R; Ohtsuru A; Iwamatsu M; Iioka T; Namba H; Seto S; Yano K; Yamashita S
J Clin Endocrinol Metab; 2002 Oct; 87(10):4821-4. PubMed ID: 12364480
[TBL] [Abstract][Full Text] [Related]
5. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor.
Zarnegar R; Brunaud L; Kanauchi H; Wong M; Fung M; Ginzinger D; Duh QY; Clark OH
Surgery; 2002 Dec; 132(6):984-90; discussion 990. PubMed ID: 12490845
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor depsipeptide represses nicotinamide N-methyltransferase and hepatocyte nuclear factor-1beta gene expression in human papillary thyroid cancer cells.
Xu J; Hershman JM
Thyroid; 2006 Feb; 16(2):151-60. PubMed ID: 16676400
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
8. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
[TBL] [Abstract][Full Text] [Related]
9. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.
Kitazono M; Goldsmith ME; Aikou T; Bates S; Fojo T
Cancer Res; 2001 Sep; 61(17):6328-30. PubMed ID: 11522619
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
11. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors.
Puppin C; D'Aurizio F; D'Elia AV; Cesaratto L; Tell G; Russo D; Filetti S; Ferretti E; Tosi E; Mattei T; Pianta A; Pellizzari L; Damante G
Endocrinology; 2005 Sep; 146(9):3967-74. PubMed ID: 15919754
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells.
Pugliese M; Fortunati N; Germano A; Asioli S; Marano F; Palestini N; Frairia R; Boccuzzi G; Catalano MG
Thyroid; 2013 Jul; 23(7):838-46. PubMed ID: 23531031
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells.
Goldsmith ME; Kitazono M; Fok P; Aikou T; Bates S; Fojo T
Clin Cancer Res; 2003 Nov; 9(14):5394-401. PubMed ID: 14614025
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.
Schmutzler C; Winzer R; Meissner-Weigl J; Köhrle J
Biochem Biophys Res Commun; 1997 Nov; 240(3):832-8. PubMed ID: 9398654
[TBL] [Abstract][Full Text] [Related]
15. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Aron JL; Parthun MR; Marcucci G; Kitada S; Mone AP; Davis ME; Shen T; Murphy T; Wickham J; Kanakry C; Lucas DM; Reed JC; Grever MR; Byrd JC
Blood; 2003 Jul; 102(2):652-8. PubMed ID: 12649137
[TBL] [Abstract][Full Text] [Related]
16. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.
Lazar V; Bidart JM; Caillou B; Mahé C; Lacroix L; Filetti S; Schlumberger M
J Clin Endocrinol Metab; 1999 Sep; 84(9):3228-34. PubMed ID: 10487692
[TBL] [Abstract][Full Text] [Related]
17. Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas.
Russo D; Manole D; Arturi F; Suarez HG; Schlumberger M; Filetti S; Derwahl M
Thyroid; 2001 Jan; 11(1):37-9. PubMed ID: 11272095
[TBL] [Abstract][Full Text] [Related]
18. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
Piekarz RL; Robey R; Sandor V; Bakke S; Wilson WH; Dahmoush L; Kingma DM; Turner ML; Altemus R; Bates SE
Blood; 2001 Nov; 98(9):2865-8. PubMed ID: 11675364
[TBL] [Abstract][Full Text] [Related]
20. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
